Revance Therapeutics Inc (RVNC)
3.025
-0.14
(-4.27%)
USD |
NASDAQ |
May 17, 16:00
3.02
0.00 (0.00%)
After-Hours: 20:00
Revance Therapeutics Cash from Investing (Quarterly): -31.71M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -31.71M |
| December 31, 2023 | 2.37M |
| September 30, 2023 | 51.59M |
| June 30, 2023 | -39.53M |
| March 31, 2023 | 95.32M |
| December 31, 2022 | 40.96M |
| September 30, 2022 | -118.44M |
| June 30, 2022 | -105.88M |
| March 31, 2022 | 44.57M |
| December 31, 2021 | 27.64M |
| September 30, 2021 | 16.81M |
| June 30, 2021 | -35.69M |
| March 31, 2021 | -38.42M |
| December 31, 2020 | -8.691M |
| September 30, 2020 | 32.50M |
| June 30, 2020 | 93.90M |
| March 31, 2020 | -105.57M |
| December 31, 2019 | 30.92M |
| September 30, 2019 | 0.918M |
| June 30, 2019 | 54.01M |
| March 31, 2019 | -103.44M |
| December 31, 2018 | 59.10M |
| September 30, 2018 | 30.36M |
| Date | Value |
|---|---|
| June 30, 2018 | 3.832M |
| March 31, 2018 | -200.32M |
| December 31, 2017 | 96.30M |
| September 30, 2017 | 14.47M |
| June 30, 2017 | 36.59M |
| March 31, 2017 | -28.57M |
| December 31, 2016 | -52.84M |
| September 30, 2016 | 92.84M |
| June 30, 2016 | 28.90M |
| March 31, 2016 | -144.39M |
| December 31, 2015 | 0.446M |
| September 30, 2015 | -1.568M |
| June 30, 2015 | -53.57M |
| March 31, 2015 | -1.726M |
| December 31, 2014 | -1.606M |
| September 30, 2014 | -2.026M |
| June 30, 2014 | -2.433M |
| March 31, 2014 | -0.91M |
| December 31, 2013 | -3.805M |
| September 30, 2013 | -0.354M |
| June 30, 2013 | -1.993M |
| March 31, 2013 | -0.25M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-118.44M
Minimum
Sep 2022
95.32M
Maximum
Mar 2023
0.3774M
Average
9.588M
Median
Cash from Investing (Quarterly) Benchmarks
| AbbVie Inc | -9.588B |
| Eli Lilly and Co | -1.178B |
| Aquestive Therapeutics Inc | -0.029M |
| Humacyte Inc | -0.391M |
| AN2 Therapeutics Inc | 26.29M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -65.94M |
| Cash from Financing (Quarterly) | 92.83M |
| Free Cash Flow | -224.20M |
| Free Cash Flow Per Share (Quarterly) | -0.7736 |
| Free Cash Flow to Equity (Quarterly) | -71.86M |
| Free Cash Flow Yield | -85.05% |